LIDDS AB (publ) (LIDDS.ST)
SEK 0.11
(-3.65%)
SEK 0.11
(-3.65%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -12.92 Million SEK | 64.71% |
| 2022 | -36.62 Million SEK | 1.74% |
| 2021 | -37.27 Million SEK | -50.35% |
| 2020 | -24.78 Million SEK | -30886.25% |
| 2019 | -80 Thousand SEK | 97.02% |
| 2018 | -2.68 Million SEK | 59.77% |
| 2017 | -6.66 Million SEK | -75.18% |
| 2016 | -3.8 Million SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | -100.0% |
| 2013 | 15.29 Thousand SEK | 18.75% |
| 2012 | 12.87 Thousand SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| 2010 | - SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -5000.00 SEK | 99.13% |
| 2024 Q1 | -577 Thousand SEK | -384.87% |
| 2023 Q1 | -118 Thousand SEK | 98.67% |
| 2023 Q3 | -119 Thousand SEK | -0.85% |
| 2023 Q4 | -119 Thousand SEK | 0.0% |
| 2023 Q2 | -118 Thousand SEK | 0.0% |
| 2023 FY | -475 Thousand SEK | 98.7% |
| 2022 Q2 | -9.93 Million SEK | -1.66% |
| 2022 Q1 | -9.76 Million SEK | -9.55% |
| 2022 FY | -36.62 Million SEK | 1.74% |
| 2022 Q4 | -8.87 Million SEK | -9.76% |
| 2022 Q3 | -8.08 Million SEK | 18.61% |
| 2021 Q4 | -8.91 Million SEK | -14.29% |
| 2021 Q3 | -7.8 Million SEK | 20.09% |
| 2021 Q2 | -9.76 Million SEK | 9.5% |
| 2021 Q1 | -10.78 Million SEK | -19.45% |
| 2021 FY | -37.27 Million SEK | -50.35% |
| 2020 Q2 | -4.16 Million SEK | 37.19% |
| 2020 Q4 | -9.03 Million SEK | -81.77% |
| 2020 FY | -24.78 Million SEK | -30886.25% |
| 2020 Q1 | -6.62 Million SEK | 73.21% |
| 2020 Q3 | -4.96 Million SEK | -19.39% |
| 2019 Q1 | - SEK | 100.0% |
| 2019 FY | -80 Thousand SEK | 97.02% |
| 2019 Q4 | -24.73 Million SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 100.0% |
| 2018 FY | -2.68 Million SEK | 59.77% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q4 | -2.77 Million SEK | -147.13% |
| 2018 Q3 | 5.88 Million SEK | 0.0% |
| 2017 Q1 | - SEK | 100.0% |
| 2017 FY | -6.66 Million SEK | -75.18% |
| 2017 Q2 | 98 Thousand SEK | 0.0% |
| 2017 Q3 | 48 Thousand SEK | -51.02% |
| 2017 Q4 | -3.68 Million SEK | -7787.35% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q4 | -3.8 Million SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 FY | -3.8 Million SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2014 Q1 | - SEK | -100.0% |
| 2014 FY | - SEK | -100.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2013 Q4 | 7647.00 SEK | 0.0% |
| 2013 Q1 | - SEK | 0.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2013 Q3 | - SEK | 0.0% |
| 2013 FY | 15.29 Thousand SEK | 18.75% |
| 2012 FY | 12.87 Thousand SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 91.958% |
| Ziccum AB (publ) | -23.28 Million SEK | 44.507% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 103.731% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 130.923% |
| Mendus AB (publ) | 28.48 Million SEK | 145.361% |
| Genovis AB (publ.) | 54 Million SEK | 123.929% |
| Intervacc AB (publ) | -13.79 Million SEK | 6.322% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 695.21% |
| Active Biotech AB (publ) | -1.67 Million SEK | -671.463% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 229.7% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 148.179% |
| Aptahem AB (publ) | 2.63 Million SEK | 591.21% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | -277.726% |
| Kancera AB (publ) | -1.96 Million SEK | -557.608% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 16881.818% |
| Fluicell AB (publ) | 1.73 Million SEK | 843.498% |
| Saniona AB (publ) | 11.78 Million SEK | 209.685% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | -152.531% |
| Biovica International AB (publ) | 6.87 Million SEK | 287.902% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 44.5% |
| AcouSort AB (publ) | 8.38 Million SEK | 254.035% |
| Xintela AB (publ) | 78 Thousand SEK | 16666.667% |
| Abliva AB (publ) | -35.66 Million SEK | 63.766% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 91.204% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 560.349% |
| OncoZenge AB (publ) | 3000.00 SEK | 430833.333% |
| Amniotics AB (publ) | -1.93 Million SEK | -569.534% |
| 2cureX AB (publ) | -37.48 Million SEK | 65.529% |
| CombiGene AB (publ) | -21.29 Million SEK | 39.307% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | -2954.846% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 101.144% |
| Camurus AB (publ) | 1.58 Billion SEK | 100.818% |
| Corline Biomedical AB | 28.38 Million SEK | 145.532% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 89.472% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 62.452% |
| I-Tech AB | 27.56 Million SEK | 146.877% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 118.213% |
| Cyxone AB (publ) | 2.61 Million SEK | 594.906% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 479.724% |
| Biosergen AB | -456 Thousand SEK | -2733.772% |
| Cantargia AB (publ) | -3.45 Million SEK | -274.442% |
| NextCell Pharma AB | -43.74 Million SEK | 70.463% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | -40.548% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 215.187% |
| Nanologica AB (publ) | -76 Thousand SEK | -16902.632% |
| SynAct Pharma AB | -778 Thousand SEK | -1560.925% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | -6595.337% |
| Stayble Therapeutics AB (publ) | - SEK | Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | 24481.132% |
| BioInvent International AB (publ) | 71.46 Million SEK | 118.083% |
| Alzinova AB (publ) | 19.87 Million SEK | 165.02% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 135.599% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 983.242% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | -86046.667% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 879.373% |
| Simris Alg AB (publ) | 2 Million SEK | 743.847% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | -260.95% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 136.515% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | -1131.84% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 512.448% |